JPH04182433A - Preventive/therapeutic agent for avian coccidiosis - Google Patents
Preventive/therapeutic agent for avian coccidiosisInfo
- Publication number
- JPH04182433A JPH04182433A JP2309534A JP30953490A JPH04182433A JP H04182433 A JPH04182433 A JP H04182433A JP 2309534 A JP2309534 A JP 2309534A JP 30953490 A JP30953490 A JP 30953490A JP H04182433 A JPH04182433 A JP H04182433A
- Authority
- JP
- Japan
- Prior art keywords
- product
- cell
- spalled
- cell wall
- cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 title claims abstract description 16
- 230000003449 preventive effect Effects 0.000 title claims abstract description 8
- 229940124597 therapeutic agent Drugs 0.000 title claims abstract description 8
- 208000003495 Coccidiosis Diseases 0.000 title claims description 15
- 206010023076 Isosporiasis Diseases 0.000 title claims description 15
- 241000271566 Aves Species 0.000 title description 2
- 210000004027 cell Anatomy 0.000 claims abstract description 49
- 230000001580 bacterial effect Effects 0.000 claims abstract description 36
- 210000002421 cell wall Anatomy 0.000 claims abstract description 18
- 241000287828 Gallus gallus Species 0.000 claims description 22
- 239000012634 fragment Substances 0.000 claims description 10
- 108090000790 Enzymes Proteins 0.000 abstract description 9
- 102000004190 Enzymes Human genes 0.000 abstract description 9
- 229940088598 enzyme Drugs 0.000 abstract description 9
- 230000000694 effects Effects 0.000 abstract description 8
- 108010014251 Muramidase Proteins 0.000 abstract description 4
- 102000016943 Muramidase Human genes 0.000 abstract description 4
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 abstract description 4
- 238000005119 centrifugation Methods 0.000 abstract description 4
- 239000004325 lysozyme Substances 0.000 abstract description 4
- 229960000274 lysozyme Drugs 0.000 abstract description 4
- 235000010335 lysozyme Nutrition 0.000 abstract description 4
- 241000193830 Bacillus <bacterium> Species 0.000 abstract description 2
- 241000186146 Brevibacterium Species 0.000 abstract description 2
- 108091005804 Peptidases Proteins 0.000 abstract description 2
- 239000004365 Protease Substances 0.000 abstract description 2
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 abstract description 2
- 230000008618 cell wall macromolecule catabolic process Effects 0.000 abstract 1
- 238000005194 fractionation Methods 0.000 abstract 1
- 230000000813 microbial effect Effects 0.000 abstract 1
- 238000004901 spalling Methods 0.000 abstract 1
- 235000013330 chicken meat Nutrition 0.000 description 15
- 238000011282 treatment Methods 0.000 description 9
- 229940079593 drug Drugs 0.000 description 8
- 230000003308 immunostimulating effect Effects 0.000 description 8
- 239000000047 product Substances 0.000 description 8
- 241000894006 Bacteria Species 0.000 description 5
- 241000186226 Corynebacterium glutamicum Species 0.000 description 5
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- 235000015097 nutrients Nutrition 0.000 description 5
- 230000016784 immunoglobulin production Effects 0.000 description 4
- 238000010297 mechanical methods and process Methods 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- QCVGEOXPDFCNHA-UHFFFAOYSA-N 5,5-dimethyl-2,4-dioxo-1,3-oxazolidine-3-carboxamide Chemical compound CC1(C)OC(=O)N(C(N)=O)C1=O QCVGEOXPDFCNHA-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 244000063299 Bacillus subtilis Species 0.000 description 3
- 102000002322 Egg Proteins Human genes 0.000 description 3
- 108010000912 Egg Proteins Proteins 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 239000003242 anti bacterial agent Substances 0.000 description 3
- 229940088710 antibiotic agent Drugs 0.000 description 3
- 238000000354 decomposition reaction Methods 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 235000014103 egg white Nutrition 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 230000003902 lesion Effects 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 210000003250 oocyst Anatomy 0.000 description 3
- 244000144977 poultry Species 0.000 description 3
- 235000013594 poultry meat Nutrition 0.000 description 3
- 230000000069 prophylactic effect Effects 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 235000014469 Bacillus subtilis Nutrition 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 241000224483 Coccidia Species 0.000 description 2
- 241000186216 Corynebacterium Species 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 239000001888 Peptone Substances 0.000 description 2
- 108010080698 Peptones Proteins 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 210000004534 cecum Anatomy 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- YPHMISFOHDHNIV-FSZOTQKASA-N cycloheximide Chemical compound C1[C@@H](C)C[C@H](C)C(=O)[C@@H]1[C@H](O)CC1CC(=O)NC(=O)C1 YPHMISFOHDHNIV-FSZOTQKASA-N 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 210000000969 egg white Anatomy 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 238000006911 enzymatic reaction Methods 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 229960001438 immunostimulant agent Drugs 0.000 description 2
- 239000003022 immunostimulating agent Substances 0.000 description 2
- 244000144972 livestock Species 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 210000005265 lung cell Anatomy 0.000 description 2
- 235000019319 peptone Nutrition 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 241001468229 Bifidobacterium thermophilum Species 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 238000011765 DBA/2 mouse Methods 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 241000223924 Eimeria Species 0.000 description 1
- 101000925662 Enterobacteria phage PRD1 Endolysin Proteins 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 235000019733 Fish meal Nutrition 0.000 description 1
- 229930182504 Lasalocid Natural products 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 241000186366 Mycobacterium bovis Species 0.000 description 1
- 238000011887 Necropsy Methods 0.000 description 1
- 206010048685 Oral infection Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 239000004721 Polyphenylene oxide Substances 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- KQXDHUJYNAXLNZ-XQSDOZFQSA-N Salinomycin Chemical compound O1[C@@H]([C@@H](CC)C(O)=O)CC[C@H](C)[C@@H]1[C@@H](C)[C@H](O)[C@H](C)C(=O)[C@H](CC)[C@@H]1[C@@H](C)C[C@@H](C)[C@@]2(C=C[C@@H](O)[C@@]3(O[C@@](C)(CC3)[C@@H]3O[C@@H](C)[C@@](O)(CC)CC3)O2)O1 KQXDHUJYNAXLNZ-XQSDOZFQSA-N 0.000 description 1
- 239000004189 Salinomycin Substances 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- JZRWCGZRTZMZEH-UHFFFAOYSA-N Thiamine Natural products CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 1
- 235000011130 ammonium sulphate Nutrition 0.000 description 1
- 230000001165 anti-coccidial effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 229940041514 candida albicans extract Drugs 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 210000000991 chicken egg Anatomy 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 229940099112 cornstarch Drugs 0.000 description 1
- 238000012364 cultivation method Methods 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 239000004467 fishmeal Substances 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- BBMULGJBVDDDNI-OWKLGTHSSA-N lasalocid Chemical compound C([C@@H]1[C@@]2(CC)O[C@@H]([C@H](C2)C)[C@@H](CC)C(=O)[C@@H](C)[C@@H](O)[C@H](C)CCC=2C(=C(O)C(C)=CC=2)C(O)=O)C[C@](O)(CC)[C@H](C)O1 BBMULGJBVDDDNI-OWKLGTHSSA-N 0.000 description 1
- 229960000320 lasalocid Drugs 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 125000001297 nitrogen containing inorganic group Chemical group 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 230000010355 oscillation Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 229920000570 polyether Polymers 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 229960001548 salinomycin Drugs 0.000 description 1
- 235000019378 salinomycin Nutrition 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- KYMBYSLLVAOCFI-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SCN1CC1=CN=C(C)N=C1N KYMBYSLLVAOCFI-UHFFFAOYSA-N 0.000 description 1
- 235000019157 thiamine Nutrition 0.000 description 1
- 229960003495 thiamine Drugs 0.000 description 1
- 239000011721 thiamine Substances 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000012138 yeast extract Substances 0.000 description 1
Landscapes
- Fodder In General (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Feed For Specific Animals (AREA)
Abstract
Description
【発明の詳細な説明】
(産業上の利用分野)
本発明は鶏コクシジウム症の予防・治療剤に関するもの
である。DETAILED DESCRIPTION OF THE INVENTION (Industrial Field of Application) The present invention relates to a prophylactic/therapeutic agent for chicken coccidiosis.
(従来の技術と問題点)
鶏コクシジウム症は胞子虫類アイメリア(Eiseri
a)属に属する数種の原虫が鶏に経口感染することによ
っておこる鶏の疾病であり、養鶏産業特にブロイラー産
業に多大な経済的損失を与える主要疾病のひとつである
。(Conventional technology and problems) Chicken coccidiosis is caused by the sporozoan Eimeria.
It is a disease of chickens caused by oral infection of several protozoa belonging to the genus a), and is one of the major diseases that causes great economic losses to the poultry industry, especially the broiler industry.
鶏コクシジウム症を予防・治療するためにモネンシシ、
サリノマイシン、ラサロシド等のポリエーテル系抗生物
質またはスルファジメトキシ、といったサルファ剤が用
いられているが、それら薬剤の多用は、薬剤耐性原虫の
出現をまねき、また薬剤自体の部体内または鶏卵白残留
の問題からその使用は著しく制限されているため、これ
ら薬剤の使用は鶏コクシジウム症予防・治療に有効かつ
安全なものではない。また近年生ワクチンの開発も進め
られているが、いまだ完全に有効なものはない。Monenshishi to prevent and treat chicken coccidiosis,
Polyether antibiotics such as salinomycin and lasalocid, or sulfa drugs such as sulfadimethoxy are used, but frequent use of these drugs can lead to the emergence of drug-resistant protozoa, and there is also the problem of the drugs themselves remaining in the body or in chicken egg white. Since their use is severely restricted, the use of these drugs is not effective or safe for the prevention or treatment of chicken coccidiosis. In recent years, progress has been made in the development of live vaccines, but there is still no one that is completely effective.
そこで鶏コクシジウム症を予防・治療すルタメの抗生物
質等の薬剤ではなく安全かつ効果の優れた新しい薬剤が
養鶏業者に望まれている。Therefore, poultry farmers are looking for new drugs that are safe and highly effective, rather than drugs such as rutame antibiotics, to prevent and treat chicken coccidiosis.
一方細菌の細胞壁成分は免疫賦活剤(アジュバント)と
して古くから知られており、細菌ミコバクテリウムボビ
スの細胞壁から調製したものについては免疫増強活性な
らびに癌免疫療法剤としての有効性が検討されている。On the other hand, bacterial cell wall components have long been known as immunostimulants (adjuvants), and those prepared from the cell wall of the bacterium Mycobacterium bovis have been investigated for their immune-enhancing activity and effectiveness as a cancer immunotherapeutic agent. There is.
(癌、第65巻493〜505ページ 1974年)ま
た家畜疾病を対称としたものとし細菌ビフィドバクテリ
ウムサーモフィラムの細胞壁から調製したものを用いた
家畜下痢予防・治療薬としての利用が報告されている(
Jpn。(Cancer, Vol. 65, pp. 493-505, 1974) Also, targeting livestock diseases, the use of a drug prepared from the cell wall of the bacterium Bifidobacterium thermophilum as a preventive and therapeutic drug for livestock diarrhea has been reported. has been done (
Jpn.
J、Vet、 Sci、 49巻235〜243ペ一
ジ1987年、特開昭62−265231)。しかしな
がらこれら免疫賦活剤の鶏コクシジウム症等の原虫感染
疾病に対する予防・治療効果は現在のところ知られてい
ない。J, Vet, Sci, Vol. 49, pp. 235-243, 1987, JP-A-62-265231). However, the preventive and therapeutic effects of these immunostimulants against protozoan infectious diseases such as chicken coccidiosis are currently unknown.
(課題を解決するための手段)
本発明らは上述の事情に鑑み鋭意研究を重ねた結果、細
菌培養菌体の機械的破砕処理さらに/もしくは酵素分解
処理を行うことによって得られる細菌細胞破砕物および
該細胞破砕物を分画して得られる細胞壁成分含有物が鶏
コクシジウム症の予防・治療効果を有することを見い出
し、本発明を完成させるに至った。(Means for Solving the Problems) As a result of extensive research in view of the above-mentioned circumstances, the present inventors have found a bacterial cell fragment obtained by mechanically crushing cultured bacterial cells and/or enzymatically decomposing them. The present inventors have also discovered that a cell wall component-containing product obtained by fractionating the cell fragments has a preventive and therapeutic effect on chicken coccidiosis, and has completed the present invention.
すなわち本発明は細菌培養菌体の機械的破砕処理さらに
/もしくは酵素分解処理を行うことによって得られる細
菌細胞破砕物および該細胞破砕物を分画して得られる細
胞壁成分含有物のうち少なくとも一種からなる鶏コクシ
ジウム予防・治療剤とそれらを含有する飼料に関するも
のである。That is, the present invention provides at least one of a bacterial cell fragment obtained by mechanically crushing and/or enzymatically decomposing a cultured bacterial cell, and a cell wall component-containing material obtained by fractionating the cell fragment. The present invention relates to preventive and therapeutic agents for chicken coccidia and feed containing them.
本発明の予防・治療剤に使用される細菌としては、その
細胞破砕物の免疫賦活効果が高いものであれば、いかな
るものも利用できるがブレビバクテリウム・ラクトファ
ーメンタム(Brevibacteriumlacto
fermentum)八TCC13869、コリネバク
テリウムダルタミカム(Corynebacteriu
m glutamicum)ATCC13060、バチ
ラス サチラス(Bacillus 5ubtilis
)ATCC13952などが例として挙げられる。As the bacteria used in the prophylactic/therapeutic agent of the present invention, any bacteria can be used as long as its cell fragments have a high immunostimulatory effect, but Brevibacterium lactofermentum (Brevibacterium lactofermentum)
fermentum) 8TCC13869, Corynebacterium daltamicum
m glutamicum) ATCC13060, Bacillus subtilis (Bacillus 5ubtilis)
) ATCC13952 is an example.
また細菌の培養には、通常これらの細菌が責化しうる栄
養源であればなんでも使用し得る。たとえばグルコース
、シュークロース等の炭水化物、エタノール、グリセロ
ール等のアルコール、酢酸、プロピオン酸等の有機酸、
大豆油等またはこれらの混合物の炭素源、酵素エキス、
ペプトン、肉エキス、コーンステイープリカー、硫安、
アンモニア等の含窒素無機有機栄養源、リン酸塩、マグ
ネシウム、鉄、マンガン、カリ等の無機栄養源、および
ビオチン、チアミン等のビタミン類を適宜配合した通常
の培地が用いられる。培養の方法としては、栄養培地の
pHを4.0〜9.5の範囲で20℃〜40°Cで12
時間〜5日間好気的に培養すればよい。Furthermore, for culturing bacteria, any nutrient source that can be used by these bacteria can generally be used. For example, carbohydrates such as glucose and sucrose, alcohols such as ethanol and glycerol, organic acids such as acetic acid and propionic acid,
Carbon sources such as soybean oil or mixtures thereof, enzyme extracts,
Peptone, meat extract, cornstarch liquor, ammonium sulfate,
A conventional culture medium containing a nitrogen-containing inorganic organic nutrient source such as ammonia, an inorganic nutrient source such as phosphate, magnesium, iron, manganese, and potassium, and vitamins such as biotin and thiamine is used. The cultivation method is to keep the pH of the nutrient medium in the range of 4.0 to 9.5 at 20°C to 40°C for 12
What is necessary is just to culture|cultivate aerobically for 5 hours to 5 days.
培養によって得られた菌体を破砕する方法は機械的方法
、酵素を利用する方法のいずれであってもよい。機械的
方法としては、例えばフレンチプレスなどを用いて約8
00〜2000kg/C11lの圧力で菌体の破砕を行
なってもよく、あるいは超音波破砕機などを用いて細胞
の破砕を行なってもよい。酵素を用いて細菌細胞を破砕
する場合には、培養菌体あるいは培養菌体の機械的破砕
処理物を生理食塩水等に懸濁しこれに細胞壁溶解酵素を
添加し菌体の細胞壁を分解する。この際用いる酵素は細
胞壁を分解する能力のあるものであれば、いかなるもの
でもよく、リゾチーム、プロテアーゼなどが代表例であ
る。酵素処理条件は公知の方法に従えばよい。機械的方
法、酵素法のいずれにおいても、細胞の破砕率は、水懸
濁による吸光度(波長560nm)fI&少による測定
で減少率30%程度以上がよ(60%程度以上が好まし
い。また、破砕率を高めるため機械的方法と酵素法を併
用することにより免疫賦活効果の高い細胞壁成分含有物
を調製できる。The method for disrupting the bacterial cells obtained by culture may be either a mechanical method or a method using enzymes. As a mechanical method, for example, using a French press etc.
Cells may be crushed under a pressure of 00 to 2000 kg/C11l, or cells may be crushed using an ultrasonic crusher or the like. When bacterial cells are disrupted using enzymes, cultured bacterial cells or mechanically disrupted cultured bacterial cells are suspended in physiological saline or the like, and a cell wall lytic enzyme is added thereto to decompose the cell walls of the bacterial cells. The enzyme used in this case may be any enzyme as long as it has the ability to decompose cell walls, and representative examples include lysozyme and protease. Enzyme treatment conditions may be according to known methods. In both the mechanical method and the enzymatic method, the cell crushing rate should be about 30% or more (preferably about 60% or more) as measured by the absorbance (wavelength 560 nm) fI & low when suspended in water. By using mechanical methods and enzymatic methods in combination to increase the rate, a cell wall component-containing product with high immunostimulatory effects can be prepared.
細菌細胞破砕物から遠心分離等の操作により細胞壁成分
含有物を分画して用いることもできる。Cell wall component-containing substances can also be fractionated from the bacterial cell fragments by centrifugation or the like and used.
本発明の予防・治療剤の使用方法としては細菌細胞の破
砕物を経口的に例えば液体のまま家禽に与えてもよいし
必要により乾燥を行い、粉末状として飼料、餌などに添
加して投与してもよい。投与時期は問わないが、コクシ
ジウム症の予防には注下時より与えることが好ましい。The prophylactic/therapeutic agent of the present invention can be used by giving crushed bacterial cells orally to poultry in the form of a liquid, or by drying it if necessary and adding it to feed, feed, etc. in the form of a powder. You may. Although the timing of administration does not matter, it is preferable to give the drug from the time of infusion to prevent coccidiosis.
また投与量は乾燥物として1日1■〜5g程度である。The dosage is about 1 to 5 g per day as a dry substance.
また飼料には乾燥物として0.01〜2%好ましくは0
.05〜1.0%添加するとよい。飼料は鶏等に用いら
れる一般的な飼料原料を適宜配合して用いることができ
る。以下、実施例により詳細に説明する。In addition, the feed contains 0.01 to 2% as dry matter, preferably 0.
.. It is recommended to add 0.05 to 1.0%. The feed can be used by appropriately mixing general feed materials used for chickens and the like. Hereinafter, it will be explained in detail using examples.
実施例−1細胞破砕物及び細胞壁成分含有物の調製
(1)細菌菌体の調製
グルコース1.0g/di、酵母エキス1.0 g/d
1、ペプトン]、 Og/a−(NHa)zSO−0,
5g/d1、K2HPO。Example-1 Preparation of cell fragments and cell wall component-containing products (1) Preparation of bacterial cells Glucose 1.0 g/di, Yeast extract 1.0 g/d
1, peptone], Og/a-(NHa)zSO-0,
5g/d1, K2HPO.
0.3glみ、KHzPOa O,1g/dfl及びM
gSO4・7H,OO,05g/みを含む培地(pH7
)を500111容フラスコに50M1入れ、115°
Cで15分間殺菌した。これにブイヨン寒天培地で30
度で1日間培養したブレビバクテリウム・ラクトファー
メンタムATCC13869コリネバクテリウム ダル
タミカムATCC13060及びバチラス サチラスA
TCC13952を一白金耳接種し、30℃で24時間
振とう培養した。0.3gl, KHzPOa O, 1g/dfl and M
Medium containing gSO4・7H, OO, 05g/min (pH 7
) in a 500111 volume flask and heated at 115°
Sterilize at C for 15 minutes. Add this to bouillon agar medium for 30
Brevibacterium lactofermentum ATCC 13869, Corynebacterium daltamicum ATCC 13060 and Bacillus subtilus A cultured for 1 day at
A loopful of TCC13952 was inoculated and cultured with shaking at 30°C for 24 hours.
培養終了後各項養液とも遠心分離して菌体を集めた。各
菌体をいずれも培養液と同量の生理食塩水ムこ懸濁して
100℃で10分間加熱処理を行い、再び遠心分離によ
り菌体を集めた。After the cultivation was completed, each nutrient solution was centrifuged to collect the bacterial cells. Each bacterial cell was suspended in the same amount of physiological saline as the culture solution, heated at 100° C. for 10 minutes, and the bacterial cells were collected again by centrifugation.
(2) 機械的破砕処理
(1)にて調製した各菌体(湿菌体)をいずれも25m
Mのリン酸緩衝液(pH7,0)に10重景%になるよ
うに懸濁した。この菌体懸濁液をステンレスボトル(5
0Id容)に入れ、超音波破砕機(UR−200P型、
トミー精工株製)により発振周波数20kHz、200
Wの出力で15分間処理した。処理後さらに遠心分離に
よって細胞壁画分含有物を分画した。(2) Each bacterial cell (wet bacterial cell) prepared in mechanical crushing treatment (1) was placed in a 25 m
The suspension was suspended in M phosphate buffer (pH 7.0) to a concentration of 10%. This bacterial cell suspension was poured into a stainless steel bottle (5
0Id volume) and ultrasonic crusher (UR-200P type,
(manufactured by Tomy Seiko Co., Ltd.) with an oscillation frequency of 20 kHz, 200
It was treated with a power of W for 15 minutes. After the treatment, the cell wall fraction content was further fractionated by centrifugation.
(3)培養菌体の酵素分解処理
(1)にて調製した各菌体(湿菌体)をいずれも固形物
としてl0IE量%含む25+++Hのリン酸緩衝液(
pH7,0)に卵白リゾチーム(シグマ社製)0.01
重量%とアクチナーゼ(科研製薬製 70000単位)
0、02重量%を添加し37°Cで12時間処理した。(3) Each bacterial cell (wet bacterial cell) prepared in (1) by enzymatic decomposition treatment of cultured bacterial cells was dissolved in 25+++H phosphate buffer containing 10% of IE as a solid substance (
pH 7.0) and egg white lysozyme (manufactured by Sigma) 0.01
Weight% and actinase (manufactured by Kaken Pharmaceutical, 70,000 units)
0.02% by weight was added and treated at 37°C for 12 hours.
その後100°Cで2分間加熱処理して酵素を失活させ
た。Thereafter, the enzyme was inactivated by heat treatment at 100°C for 2 minutes.
(4)機械的破砕処理物の酵素分解処理(2)にて調製
した細胞の機械的処理物を固形物として10重量%含む
251リン酸緩衝液(pH7,0)に卵白リゾチーム(
シグマ社製)0.1重量%とアクチナーゼ(科研製薬製
70000単位)0.2重量%を添加し、37℃で12
時間処理した。その後100°Cで2分間加熱処理して
酵素を失活させた。(4) Egg white lysozyme (
0.1% by weight (manufactured by Sigma) and 0.2% by weight of actinase (70000 units manufactured by Kaken Pharmaceutical Co., Ltd.) were added, and
Time processed. Thereafter, the enzyme was inactivated by heat treatment at 100°C for 2 minutes.
(5)マウス肺臓細胞を用いた免疫賦活効果RPM11
640培地に10%ウシ胎仔非働血清、5×10−5M
2メルカプトエタノールを添加し、濾過滅菌した。これ
に10週令のメスDBA/ 2系マウスの肺臓より調製
した肺臓・浮遊細胞を2.5×106個/dになるよう
に懸濁した。それに(1)、(2) (3)及び(4)
で調製した細菌の菌体並びに酵素分解処理物を各濃度に
なるように添加し、37°C・5%C02インキユベー
タ内で4日間培養した。培養後、培養上清を1%のウシ
血清アルブミンを含んだ0.01M トリス塩酸緩衝液
(pH8,1)で1000倍に希釈したのち、ELIS
A法によって培養液中に生産された総マウスIgM量を
測定することによって各添加調製物の免疫賦活効果を測
定した。なお、免疫賦活作用効果を検定するための標準
物質としては、病原大腸菌由来のリポ多1!(LPS)
を用いた。(5) Immunostimulatory effect RPM11 using mouse lung cells
10% non-working fetal calf serum in 640 medium, 5 x 10-5M
2-mercaptoethanol was added and filter sterilized. Lung floating cells prepared from the lungs of a 10 week old female DBA/2 mouse were suspended in this at a concentration of 2.5 x 106 cells/d. Also (1), (2) (3) and (4)
The bacterial cells and enzymatically decomposed products prepared in step 1 were added to each concentration and cultured for 4 days at 37°C in a 5% CO2 incubator. After culturing, the culture supernatant was diluted 1000 times with 0.01M Tris-HCl buffer (pH 8.1) containing 1% bovine serum albumin, and then subjected to ELIS.
The immunostimulatory effect of each additive preparation was determined by measuring the total amount of mouse IgM produced in the culture medium by Method A. In addition, as a standard substance for testing the immunostimulatory effect, Lipopoly1! derived from pathogenic Escherichia coli is used. (LPS)
was used.
その結果を第1図に示した。The results are shown in Figure 1.
第1図は各属の殺菌処理菌体とその酵素分解処理物のマ
ウスIgM・抗体産生との関係を示したものである。同
図において横軸は添加濃度(μg/d)を示し、縦軸は
肺臓培養細胞の培養液中に産生された総マウスIgMの
濃度(μg/d)を示す。FIG. 1 shows the relationship between sterilized bacterial cells of each genus and mouse IgM/antibody production of their enzymatically decomposed products. In the figure, the horizontal axis shows the added concentration (μg/d), and the vertical axis shows the concentration (μg/d) of total mouse IgM produced in the culture solution of cultured lung cells.
黒丸破線は実施例(1)に従って調製した殺菌処理菌体
の場合、
白丸破線は実施例(2)に従って調製した機械的破砕処
理物の場合、黒丸実線は実施例(3)に従って調製した
酵素的分解処理の場合、白丸実線は実施例(4)に従っ
て調製した菌体の機械的破砕処理と酵素分解処理をあわ
せて行なったものの場合を各々示した。The broken line with black circles indicates the case of the sterilized bacterial cells prepared according to Example (1), the broken line with white circles indicates the case of the mechanically disrupted cells prepared according to Example (2), and the solid line with black circles indicates the case of the enzymatically crushed cells prepared according to Example (3). In the case of decomposition treatment, the solid white circles indicate the cases in which the bacterial cells prepared according to Example (4) were subjected to both mechanical crushing treatment and enzymatic decomposition treatment.
第1図から明らかなように実施例(2)(3)(4)の
培養菌体の破砕処理物は実施例(1)の殺菌菌体そのも
のよりも抗体産生増強能は高く、LPSでの抗体産生の
最大値(150μg/−)を上まわる高い活性を示し、
優れた免疫賦活効果を有していることがわかる。As is clear from FIG. 1, the disrupted cultured cells of Examples (2), (3), and (4) have a higher ability to enhance antibody production than the sterilized cells of Example (1), and are more effective than LPS. It shows high activity exceeding the maximum value of antibody production (150μg/-),
It can be seen that it has an excellent immunostimulatory effect.
実施例−2細胞破砕物及び細胞壁成分含有物を含む飼料
の調製と効果
(1)各種菌体細胞破砕物の鶏コクシジウム症に対する
効果
市販ブロイラーヒナ76羽を19羽ずつ4区にわけた。Example 2 Preparation and Effects of Feed Containing Crushed Cells and Materials Containing Cell Wall Components (1) Effect of various crushed bacterial cells on chicken coccidiosis Seventy-six commercially available broiler chicks were divided into four groups of 19 each.
1区はコントロール(非投与群)とし、他の3区は(4
)に従って調製したブレビバクテリウムATCC138
69、コリネバクテリウム グルタミカムATCC13
060及びバチラス サチラスATCC13952の細
菌の酵素分解処理物の乾燥粉末を抗生物質を含まないブ
ロイラー前期マツシュ飼料(とうもろこしかす64%、
植物性油かす24%、魚粉8%、その他灰分等4%)に
0.3%添加し、給与した。One area is the control (non-administration group), and the other three areas are (4
) Brevibacterium ATCC138 prepared according to
69, Corynebacterium glutamicum ATCC13
060 and Bacillus subtilis ATCC 13952, the dry powder of the enzymatically decomposed bacteria was used as an antibiotic-free broiler early matush feed (64% cornmeal,
0.3% was added to 24% vegetable oil cake, 8% fishmeal, and 4% other ash, etc.) and fed.
全区とも7日令にアイメリアテネラオーシストを104
個/羽経口投与し、強制的に感染させた。104 Eimeriatenela oocysts in all districts at 7 days old
The bird was orally administered per bird to forcefully infect the bird.
感染後7日、各区5羽剖検し肉眼的剖検所見により病変
を観察した。病変の程度で0から4(4はと重症)のス
コアをつけ平均値を算出、判定基準は常法に従った。さ
らに盲腸を採材し1gあたりのオーシスト数を計数した
。そして得られたデータについては平均値差の検定(D
UNCAN’S MULTIPLERANGE TES
T)により統計処理を行った。その結果を表−1にしめ
した。Seven days after infection, 5 birds in each group were necropsied and lesions were observed based on macroscopic necropsy findings. The severity of the lesions was scored from 0 to 4 (4 is severe) and the average value was calculated, using standard methods for evaluation. Furthermore, the cecum was sampled and the number of oocysts per 1 g was counted. Then, the obtained data are tested for mean difference (D
UNCAN'S MULTIPLE RANGE TES
Statistical processing was performed using T). The results are shown in Table 1.
表−1各種菌体細胞破砕物の鶏コクシジウム症に対する
効果
表−1から明らかなように投与区では感染後の死亡例も
なくまた平均病変値も低く、盲腸内オーシスト数も有意
に低下していることから鶏コクシジウム症に対する効果
は明らかである。Table 1: Effect of various bacterial cell fragments on chicken coccidiosis As is clear from Table 1, there were no cases of death after infection in the treated groups, the average lesion value was low, and the number of oocysts in the cecum was significantly reduced. The effect on chicken coccidiosis is clear.
(2)各種処理による破砕物の鶏コクシジウム症に対す
る効果
市販ブロイラーヒナ114羽を19羽ずつ6区にわけた
。1区はコントロール(非投与群)とし他の5区には実
施例(1)(2) (3) (4)に従って調製した。(2) Effect of various treatments on chicken coccidiosis of shredded products 114 commercially available broiler chicks were divided into 6 groups of 19 each. One group was a control (non-administration group), and the other five groups were prepared according to Examples (1), (2), (3), and (4).
ブレビバクテリウム ラクトファーメンタムATCC1
3869の菌体及びその処理物の乾燥粉末を飼料に0.
7%添加して投与あるいは乾燥粉末を10g/a含む水
溶液を毎日1回2dずつ経口的に直接投与した。飼育に
は全区とも抗生物質を含まないブロイラー前期マツシュ
飼料を用いた。以下(1)項と同様に鶏コクシジウム強
制感染試験を行なった。そめ結果を表−2にしめした。Brevibacterium lactofermentum ATCC1
3869 cells and dried powder of the processed product were added to the feed.
The mice were administered at a concentration of 7%, or an aqueous solution containing 10 g/a of dry powder was directly orally administered once daily for 2 days. Early broiler Matushu feed, which does not contain antibiotics, was used for breeding in all plots. A chicken coccidia forced infection test was conducted in the same manner as in section (1) below. The results are shown in Table 2.
A: C,D 、E 、 Fで1%の危険率で有意差
あり菌体の機械的破砕処理物、酵素分解処理物または両
方を併用したものは殺菌処理菌体よりも抗コクシジウム
効果が高い。 また飼料に添加しても、直接投与しても
有効である。A: There is a significant difference at a 1% risk rate between C, D, E, and F. Mechanically disrupted bacterial cells, enzymatically decomposed bacterial cells, or a combination of both have higher anti-coccidial effects than sterilized bacterial cells. . It is also effective whether added to feed or administered directly.
第1図は各属の殺菌処理菌体とその酵素分解処理物のマ
ウスIgM・抗体産生との関係を示すグラフである。FIG. 1 is a graph showing the relationship between sterilized bacterial cells of each genus and mouse IgM/antibody production of the enzymatically decomposed products.
Claims (1)
素分解処理を行うことによって得られる細菌細胞破砕物
および該細胞破砕物を分画して得られる細胞壁成分含有
物のうち少なくとも一種からなる鶏コクシジウム症の予
防治療剤 2、請求項1記載の鶏コクシジウム症の予防治療剤を含
有する飼料。[Scope of Claims] 1. Bacterial cell fragments obtained by mechanically crushing cultured bacterial cells and/or enzymatically decomposing them, and cell wall component-containing products obtained by fractionating the cell fragments. Preventive and therapeutic agent for chicken coccidiosis 2 comprising at least one of these, a feed containing the preventive and therapeutic agent for chicken coccidiosis according to claim 1.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2309534A JP2897410B2 (en) | 1990-11-15 | 1990-11-15 | Preventive and therapeutic agent for chicken coccidiosis |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2309534A JP2897410B2 (en) | 1990-11-15 | 1990-11-15 | Preventive and therapeutic agent for chicken coccidiosis |
Publications (2)
Publication Number | Publication Date |
---|---|
JPH04182433A true JPH04182433A (en) | 1992-06-30 |
JP2897410B2 JP2897410B2 (en) | 1999-05-31 |
Family
ID=17994176
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2309534A Expired - Fee Related JP2897410B2 (en) | 1990-11-15 | 1990-11-15 | Preventive and therapeutic agent for chicken coccidiosis |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP2897410B2 (en) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1995004539A1 (en) * | 1993-08-11 | 1995-02-16 | Ahc Inc. | Immunopotentiator and method of immunopotentiating animal with the same |
EP0681787A3 (en) * | 1994-05-10 | 1996-10-23 | Finnfeeds Int Ltd | Use of an enzyme for manufacturing an agent for the treatment and/or prophylaxis of coccidiosis. |
EP1103190A1 (en) * | 1999-11-26 | 2001-05-30 | Nisshin Flour Milling Co., Ltd. | Feed for prevention and/or treatment of coccidiosis |
WO2004032645A1 (en) * | 2002-10-11 | 2004-04-22 | Erber Aktiengesellschaft | Food additive and/or drinking water additive for domestic animals |
DE102004025869A1 (en) * | 2004-05-27 | 2005-12-22 | Süd-Chemie AG | Bioprotektivum |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA3177327A1 (en) * | 2020-05-14 | 2021-11-18 | Andrew A. Dahl | Use of tlr4 modulator in the treatment of coccidiosis |
-
1990
- 1990-11-15 JP JP2309534A patent/JP2897410B2/en not_active Expired - Fee Related
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1995004539A1 (en) * | 1993-08-11 | 1995-02-16 | Ahc Inc. | Immunopotentiator and method of immunopotentiating animal with the same |
EP0681787A3 (en) * | 1994-05-10 | 1996-10-23 | Finnfeeds Int Ltd | Use of an enzyme for manufacturing an agent for the treatment and/or prophylaxis of coccidiosis. |
US5624678A (en) * | 1994-05-10 | 1997-04-29 | Finnfeeds International Limited | Method and composition for treatment and/or prophylaxis of coccidiosis |
EP1103190A1 (en) * | 1999-11-26 | 2001-05-30 | Nisshin Flour Milling Co., Ltd. | Feed for prevention and/or treatment of coccidiosis |
JP2001151675A (en) * | 1999-11-26 | 2001-06-05 | Nisshin Flour Milling Co Ltd | Feed for prevention and/or treatment of coccidiosis |
US6379694B1 (en) | 1999-11-26 | 2002-04-30 | Nisshin Feed Inc. | Feed for prevention and/or treatment of coccidiosis |
JP4680339B2 (en) * | 1999-11-26 | 2011-05-11 | 日清丸紅飼料株式会社 | Feed for prevention and / or treatment of coccidiosis |
WO2004032645A1 (en) * | 2002-10-11 | 2004-04-22 | Erber Aktiengesellschaft | Food additive and/or drinking water additive for domestic animals |
DE102004025869A1 (en) * | 2004-05-27 | 2005-12-22 | Süd-Chemie AG | Bioprotektivum |
Also Published As
Publication number | Publication date |
---|---|
JP2897410B2 (en) | 1999-05-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US4710379A (en) | Intestinal microflora-improving agent | |
JP6367974B2 (en) | Bacillus strain having improved productivity of fermented soybean meal and method for producing fermented soybean meal using the same | |
EP0416892A1 (en) | Agents for the prevention and treatment of diarrhoea | |
KR100204935B1 (en) | Feed composition for mother sows | |
CA1266234A (en) | Method of binding microflora | |
US5759554A (en) | Immunostimulatory bacterial cell wall traction | |
KR101807328B1 (en) | Dna damage repair promoter for oral application, and elastase activity inhibitor for oral application | |
Soulsby | Immunization against Ascaris lumbricoides in the guinea pig | |
EP3950928A1 (en) | Kimchi lactic acid bacteria lactobacillus sakei wikim0109 having efficacy for relief of arthritis | |
JP3648233B2 (en) | Feed composition | |
JP4565057B2 (en) | Novel lactic acid bacteria with high ability to induce immunoglobulin A | |
JPH04182433A (en) | Preventive/therapeutic agent for avian coccidiosis | |
CN1093578A (en) | The prevention of fish and Crustaceans virosis and therapeutic agent and feedstuff | |
JP2526733B2 (en) | Agent for preventing and treating bacterial diseases of fish and crustaceans | |
CN1162089C (en) | Microecological regulator for animal and fowl | |
CN110430763A (en) | Feed addictive prescription and its preparation and application | |
US7678557B2 (en) | Methods for the accumulation and retention of immune-enhancing, bacterial-derived ribonucleotides (ORN) in bacteria | |
KR20010103645A (en) | Composition and Method for Increasing Weight Gain and Feed Efficiency | |
JP2621588B2 (en) | Prevention and treatment of white and diarrhea in livestock | |
GB2077101A (en) | Antiallergic composition containing streptococci | |
KR20200094590A (en) | Pharmacological Composition Comprising Lactic acid Bacteria Fermented Product of Morus alba Extract for Prevention or Treatment of Depressive Disorder or Anxiety Disorder | |
WO1995004539A1 (en) | Immunopotentiator and method of immunopotentiating animal with the same | |
JP3272023B2 (en) | Leukopenia treatment | |
JP2841237B2 (en) | An antihypertensive agent comprising a water extract of bacteria having an antihypertensive action as an active ingredient | |
JPS59128333A (en) | Growth promotor for domestic fowl |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20080312 Year of fee payment: 9 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20090312 Year of fee payment: 10 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20090312 Year of fee payment: 10 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100312 Year of fee payment: 11 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100312 Year of fee payment: 11 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100312 Year of fee payment: 11 |
|
LAPS | Cancellation because of no payment of annual fees |